chronic obstructive pulmonary disease
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Target Group (1) (i) Have had at least one medical checkup between January 2017 and December 2019 (ii) Enrolled for one year in the year of the checkup (iii) Aged 40 years or older at the time of the checkup (iv) FEV1% and FEV1 have been measured Target Group (2) (i) Have a medical checkup in each year (3 years) from January 2017 to December 2019 (ii) Have been enrolled for three years from January 2017 (iii) Aged 40 years or older as of January 2017 (iv) Have airflow limitation as of 2017 (v) Have had FEV1% and FEV1 measured continuously for 3 years
Exclusion criteria
Exclusion criteria: No setting
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of airflow limitation and COPD diagnosis rate | — |
Secondary
| Measure | Time frame |
|---|---|
| - Percentage of patients by severity of airflow limitation using %FEV1 - FEV1%, FEV1, prevalence of disease, and prescription drugs by COPD diagnosis - FEV1%, FEV1, and prevalence of disease by frailty classification - FEV1% and FEV1 by COPD diagnosis and smoking status over 3 years | — |
Countries
Japan
Contacts
Kracie, Ltd. Pharmaceutical Research Promotion Department, Pharmaceutical Division